Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Elife|January 31, 2025
Role of hepatocyte RIPK1 in maintaining liver homeostasis during metabolic challengesWeigao Zhang, Hu Liu, Danyang Zhang, et al.
Infectious Medicine|November 28, 2023
Transmission risk of asymptomatic SARS-CoV-2 infection: a systematic review and meta-analysisCi Zhang, Chao Zhou, Wanqing Xu, et al.
Infection and Drug Resistance|December 16, 2024
A Retrospective Data Audit of Outcome of Moderate and Severe Covid-19 Patients Who Had Received MP and Dex: A Single Center StudyYupeng Li, Chuanchuan Dong, Yanqing Xing, et al.
Acta Pharmaceutica Sinica. B|April 27, 2026
Engineered bacteria reprogram tumor microenvironment <i>via</i> cell senescence and neutrophil extracellular traps degradationWanfa Dong, Chenyang Li, Jiqiang Lu, et al.
Cancer|February 26, 2024
Dual CTLA-4 and PD-1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first-in-human, dose-escalation, and dose-expansion studySarwan Bishnoi, Dusan Kotasek, Morteza Aghmesheh, et al.
The Lancet. Oncology|January 17, 2022
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trialCaicun Zhou, Ziping Wang, Yuping Sun, et al.
Targeted Oncology|September 4, 2024
A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or LymphomaJifang Gong, Ye Guo, Yanqiao Zhang, et al.
British Journal of Cancer|September 21, 2023
A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancerDaphne Day, John J Park, Jermaine Coward, et al.
JAMA Oncology|July 31, 2025
Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor-Positive and ERBB2-Negative Advanced Breast Cancer After Endocrine Therapy: A Randomized Clinical TrialZhonghua Tao, Jian Zhang, Qiufan Zheng, et al.
Pageof 7